ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

1755 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients. The Research and Development (R\&D) Blueprint of the World Health Organization (WHO) has included LF in the list of priority diseases for urgent research and development.

The INTEGRATE consortium is an unprecedented international collaboration on Lassa fever of 15 partners from 10 countries across West Africa, Europe and North America and across several disciplines (epidemiological researchers, social scientists, medical health facility professionals, humanitarian actors, etc.).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.

NCT02859350

Malaria

COMPLETED PHASE1

Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs and Vectors of the Disease

NCT06692985

Cutaneous Leishmaniasis

COMPLETED

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

NCT00415051

Rift Valley Fever

COMPLETED PHASE2

Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)

NCT02283099

Hemorrhagic Fever, Ebola

COMPLETED PHASE1

Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

NCT01360762

Visceral Leishmaniosis HIV-infection/Aids

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The INTEGRATE study is a platform, multinational, multicentre, sequential, seamless phase II-III, controlled, randomised, superiority trial in open-label parallel arms. Three arms will be assessed and compared to the SCD. Its primary objective is to compare the efficacy of each Investigational Medical Product (IMP) to Standard of Care Drug (SCD) to prevent death or organ failure in hospitalized patients with confirmed LF. Secondary objectives will be i) to compare the safety and tolerability of each IMP and SCD, ii) to compare the efficacy of each IMP and SCD on clinical, virological and biological parameters, iii) to describe the pharmacokinetics of each IMP and iv) to develop a pharmacokinetics / pharmacodynamics model for each IMP informing about optimal dosing regimens and dose-response relationship.

1. Objectives

1.1 Primary objective The primary objective of the trial is to compare the efficacy of each IMP and SCD to prevent death or organ failure in hospitalized participants with confirmed LF.

1.2. Secondary objectives
* To compare the safety and tolerability of each IMP and SCD
* To compare the efficacy of each IMP and SCD on clinical, virological and biological parameters
* To describe the pharmacokinetics of each IMP
* To develop a pharmacokinetics / pharmacodynamics model for each IMP informing about optimal dosing regimens and dose-response relationship
2. Design

* Phase II: comparative controlled design
* Phase III: Whitehead's sequential double triangular design
3. Sample size:

In the current version of the protocol (if all sub-protocols start at once):
* 3 IMPs go into phase III: N= 732
* 2 IMPs go into phase III: N= 585
* 1 IMP go into phase III: N= 438
4. Duration

* Hospitalization: 10 days
* Follow-up: 28 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lassa Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

a) Arms

Intervention/ treatement

Arm 1: SCD: ribavirin Arm:2 Favirpiravir 1600 Arm 3: Favipiravir 1200+ribavirin Arm 4: Ribavirin + dexamethasone

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Participant, Investigator, Outcomes Assessor

Intervention Type DRUG

Interventional Medicinal Product (IMP)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Favipiravir

Interventional Medicinal Product (IMP)

Intervention Type DRUG

Ribavirin

Control arm

Intervention Type DRUG

Dexamethasone

Interventional Medicinal Product (IMP)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard of care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical disease with signs and symptoms suggestive for LF
* Positive plasma LASV RT-PCR
* Participant requires hospitalization per the local guidelines
* Participant or their legally authorized representative is able and willing to sign the informed consent

• Age ≥ 18 years old

• Age ≥ 18 years old

• Age ≥ 12 years old

Exclusion Criteria

• Unwilling to provide informed consent

• Positive pregnancy test
* Unwilling to provide informed consent
* History of allergic reaction or other contra-indication to ribavirin according to the Reference safety document
* Received drug therapy for Lassa fever (excluding supportive care) prior to inclusion
* Has received a vaccine against LF
2. Sub-protocols

2.1 Favipiravir high dose sub-protocol

• Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)

• Treatment contraindicated with favipiravir according to the Reference safety document

• Pre-existing liver failure
* Severe symptomatic gout/hyperuricemia
* History of QT prolongation or arrhythmia or other cardiac disorders
* PR interval ≥ 200 ms
* Hypersensitivity to excipients
* Inability to take oral drug (e.g. encephalopathy, severe vomiting)

2.2. Favipiravir-Ribavirin sub-protocol

• Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)

• Treatment contraindicated with favipiravir according to the Reference safety document

• Pre-existing liver failure

• Severe symptomatic gout/hyperuricemia

• History of QT prolongation or arrhythmia or other cardiac disorders

• PR interval ≥ 200 ms

• Hypersensitivity to excipients

• Inability to take oral drug (e.g. encephalopathy, severe vomiting)

2.3. Dexamethasone sub-protocol

* Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)
* Known intolerance and contra-indications to ribavirin or dexamethasone
* Patients who already received a corticosteroid within the preceding 7 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No